Antisense Therapeutics Ltd
Overview
Antisense Therapeutics Limited (ATL) is an Australian, publicly traded Biopharmaceutical discovery and development company. The company has also established a Level 1 American Depositary receipt program.
ATL’s mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets.
The company is developing a pipeline of antisense drugs via its collaboration with Isis Pharmaceuticals Inc, a world leader in antisense drug discovery and development.
Through its relationship with Isis, ATL has access to a broad range of intellectual property, know-how and technical expertise which allows it to develop a substantial product pipeline.
ATL's strategy is to successfully commercialise its product pipeline via licensing agreements with larger biotechnology and pharmaceutical companies. The company has recently licensed its lead drug ATL1102 for multiple sclerosis and other indications to Teva Pharmaceutical Industries Ltd, a top 20 global pharmaceutical company.
Main business focus/
Listing by sector:
- Drug Discovery & Development
Competitive Advantages
Antisense drugs work by entering cells and blocking the protein-producing activity of specific genes. Most current drugs act on proteins directly. Antisense compounds work at an earlier stage, preventing production of disease-causing proteins. Compared to conventional drugs, antisense potentially provide more efficient and predictable drug discovery, based on increased specificity of action and uniformity of methods of manufacture, formulation and delivery.
Antisense drugs should also have advantages as medicines as they can be designed to be more selective than traditional therapy, resulting in more effective and potentially less toxic drugs. The antisense technology available to ATL under its agreement with Isis allows it to develop antisense drugs with convenient dosing regimens and potentially more acceptable routes of administration for a broad range of diseases. The 2nd generation antisense platform is a mature technology with multiple compounds now in late stage clinical development.
Technology/IP
ATL’s pipeline consists of:
ATL1102, a 2nd generation antisense inhibitor directed to the VLA-4 receptor, which is in Phase II clinical trials for multiple sclerosis and has recently been licensed to Teva Pharmaceuticals Industries Ltd.
ATL1103, a 2nd generation antisense inhibitor directed to the growth hormone receptor, which is in development for the growth disorder acromegaly with potential application in the eye disorder diabteic retinopathy.
The company also has a 3rd compound, ATL1101, a 2nd generation antisense drug directed to the IGF-1 receptor in research for prostate cancer.
Corporate Alliances/Partnerships
Isis Pharmaceuticals Inc, Carlsbad, California, USA.
Teva Pharmaceutical Industries Ltd, Petach-Tikva, Israel
Partnering Opportunities
The Company would be interested in discussing partnering opportunities for its pipeline compounds ATL1101 and ATL1103
Contact Details
| Contact person | Mark Diamond |
|---|---|
| Job Title | Managing Director |
| Address | Level 1, 10 Wallace Avenue |
| City/Suburb | Toorak |
| State | Victoria |
| mark.diamond@antisense.com.au | |
| Phone | +61 3 9827 8999 |
| Fax | +61 3 9827 1166 |
| Website | http://www.antisense.com.au |
